evelo-logo.png
Evelo Biosciences Provides Clinical Updates
26 avr. 2023 07h30 HE | Evelo Biosciences, Inc.
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV...
evelo-logo.png
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
16 mars 2023 07h00 HE | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally...
evelo-logo.png
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
27 févr. 2023 06h00 HE | Evelo Biosciences, Inc.
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been...